Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × NSCLC × Drug Therapy × Clear all

Phase

Phase 2 4 Phase NA 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Neoplasms 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Colorectal Neoplasms 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Sarcoma, Ewing 1 SCLC 1 Retinoblastoma 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Oligometastatic Disease 1 Neoplasms, Germ Cell and Embryonal 1 Nasopharyngeal Carcinoma 1 NSCLC 1 Mouth Neoplasms 1 Melanoma 1 Lymphoma, Follicular 1 Lymphoma 1 Lung Neoplasms 1 Locally Advanced Resectable Rectal Cancer 1 Glioblastoma 1 Gestational Trophoblastic Disease 1 Gastrointestinal Neoplasms 1

Interventions

Pemetrexed 2 Gefitinib 2 spartalizumab 1 aflutinib 1 Tyrosine Kinase Inhibitors 1 Thalidomide 1 Radiosurgery 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Axitinib 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

The First Affiliated Hospital of Henan University of Science and Technology

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡